Paxlovid unlikely contributes to COVID-19 rebound; a roundup of 2023 guidelines

Ella Castle

January 02, 2024 1 min read Add topic to email alerts Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . “ data-action=”subscribe”> Subscribe We were unable to process […]

January 02, 2024

1 min read

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected].

Two separate analyses of studies and trials suggest that COVID-19 rebound is not linked to Paxlovid or other antiviral drugs.

The findings contradict other studies that indicated a higher frequency of COVID-19 rebound among people treated with Paxlovid (nirmatrelvir/ritonavir, Pfizer).

Guidelines_Adobe Stock

New guidance was published in 2023 for STD prevention, diabetic foot infections, infective endocarditis and more. Image Source: Adobe Stock

“Rebound is typically described as a recurrence of symptoms after recovery or a new positive viral test after testing negative,” Pragna Patel, MD, MPH, DRM&H, chief medical officer in the Coronavirus and Other Respiratory Viruses division of the CDC’s National Center for Immunization and Respiratory Diseases, told Healio. “We found that there was no consistent association between treatment for COVID-19 and COVID-19 rebound. Also, we found that COVID-19 rebound can happen among patients whether they received antiviral treatments or not.”

It was the top story in infectious disease last week.

Another top story was a collection of articles about ID-related guidelines released in 2023, including recommendations on sexually transmitted disease prevention, diabetic foot infections and more.

Read these and more top stories in infectious disease below:

Paxlovid unlikely to contribute to COVID-19 rebound

SARS-CoV-2 rebound risk is more likely related to the individual person, rather than reinfection or resistance to treatment such as Paxlovid, according to two studies. Read more.

Doxy-PEP, diabetic foot infections and more: The year in ID guidelines

New guidance was published in 2023 for STD prevention, diabetic foot infections, infective endocarditis and more. Read more.

COVAX to end as COVID-19 vaccines move to routine immunization programs

COVAX, the multinational program launched in 2020 to deliver COVID-19 vaccines to low- and lower-middle income countries, will end on Dec. 31, 2023, as the vaccines shift to routine immunization programs. Read more.

Pneumonia, candidiasis and more: The non-vaccine approvals of 2023

The FDA in 2023 approved treatments for several hospital-associated infections and fully approved a long-used COVID-19 medication, among other non-vaccine-related regulatory decisions. Read more.

Developments in hepatitis care: New CDC recommendations and more

As viral hepatitis continues to be a major health concern in the infectious disease field, recent research has highlighted the importance of testing and treatment. Read more.

Next Post

Four health and fitness trends to watch in 2024

Open this photo in gallery: Carlos Suarez lifts weights as part of his daily training regimen ahead of the Pan Am Games in Toluca, Mexico, on June 6, 2019.Rebecca Blackwell/The Associated Press When you’re forecasting fitness trends, you can’t help feeling that Albert Einstein was right in claiming that the […]
Four health and fitness trends to watch in 2024

Subscribe US Now

situs judi bola Daftar sekarang dengan cara klik link login slot via dana 24 jam terpercaya, join sekarang slot gacor online dengan pilihan platform game slot pragmatic play paling favorit tahun 2023. akun pro thailand idn poker